- Home
- ADPT
as 11-15-2024 4:00pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | 709 | City: | SEATTLE |
| Market Cap: | 749.7M | IPO Year: | 2019 |
| Target Price: | $6.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.28 - $6.70 | Next Earning Date: | 11-07-2024 |
| Revenue: | $177,282,000 | Revenue Growth: | -1.34% |
| Revenue Growth (this year): | 3.82% | Revenue Growth (next year): | 20.38% |
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Taylor Stacy L | ADPT | SVP and General Counsel | Aug 22 '24 | Sell | $4.50 | 26,922 | $121,079.00 | 139,365 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
Zacks
4 days ago
Is Cardinal Health (CAH) Outperforming Other Medical Stocks This Year?
Simply Wall St.
8 days ago
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
9 days ago
Q3 2024 Adaptive Biotechnologies Corp Earnings Call
GuruFocus.com
9 days ago
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ...
Zacks
9 days ago
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks
9 days ago
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
10 days ago
Adaptive Biotechnologies: Q3 Earnings Snapshot
Compare ADPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.